BeiGene Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (16)

Latest Posts

About This Stock More About This Stock
Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services
Article By: ChinaBio® Today
Sunday, January 20, 2019 10:38 AM EST
MabPlex, a biologics CDMO, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital. MabPlex offers biologics development and manufacturing services, including mAbs, recombinant proteins, ADCs and bispecifics.
In this article: AZN, IRWD, CBMG, BGNE
Read
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EST
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Week In Review: Biosense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy
Article By: ChinaBio® Today
Saturday, October 13, 2018 4:59 PM EST
Biosense Global, a New Jersey-Suzhou in-licensing company, exercised a $75 million option for China rights to an active lupus immunotherapy developed by Neovacs, following a successful Phase II trial of the therapeutic vaccine, IFNalpha Kinoid.
In this article: MEIP, BGNE
Read
Week In Review: Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO
Article By: ChinaBio® Today
Saturday, September 8, 2018 4:22 PM EST
Hansoh, a China pharma based in Lianyungang, Jiangsu province, has applied to stage an IPO on the Hong Kong exchange. Unlike most companies seeking Hong Kong IPOs, Hansoh is both profitable and established.
In this article: GSK, LLY, BGNE, ZLAB, ROG, HCM, MRK
Read
Week In Review: Nearly $1 Billion In Cross-Border China Biopharma Deals
Article By: ChinaBio® Today
Saturday, September 1, 2018 4:06 PM EST
WeDoctor, Mason Group and Aldworth Management will pay up to $510 million to acquire an 89.5% stake in Genea, an Australian fertility treatment company. Genea's assisted reproductive technologies are used in more than 600 clinics in 60 countries.
In this article: BGNE
Read

PARTNER HEADLINES

Latest Tweets for $BGNE

No tweets yet!